What is the AI rating for AKTS?

Aktis Oncology, Inc. (AKTS) has an AI rating of HOLD with 15% confidence, based on fundamental analysis of SEC EDGAR filings.

What are the key strengths of AKTS?

Recent insider activity indicates engaged management team. Biopharmaceutical sector allows for potential pipeline value creation. Listed on Nasdaq suggests prior compliance with exchange standards

What are the risks of investing in AKTS?

Complete absence of financial reporting data across income statement, balance sheet, and cash flow metrics. No revenue generation apparent, typical of pre-commercialization biotech. Inability to assess liquidity, solvency, or operational viability without financial statements

What is AKTS's revenue growth rate?

Aktis Oncology, Inc. (AKTS) has a revenue growth rate of N/A year-over-year, based on the latest SEC EDGAR filings.

Does AKTS pay dividends?

Aktis Oncology, Inc. (AKTS) does not currently pay dividends.

Where can I find AKTS SEC filings?

Official SEC filings for Aktis Oncology, Inc. (CIK: 0002035832) including 10-K annual reports, 10-Q quarterly reports, and 8-K current reports are available on SEC EDGAR at sec.gov.

What is AKTS's EPS growth?

Aktis Oncology, Inc. earnings per share (EPS) growth is N/A year-over-year. Current diluted EPS is $0.00.

AKTS Stock Analysis - Aktis Oncology, Inc. AI Rating & Fundamentals

Name: Aktis Oncology, Inc. (AKTS) Stock
Brand: Aktis Oncology, Inc.
Rating: 3 (1 reviews)

Investment Thesis

Unable to perform meaningful fundamental analysis due to absence of reported financial data across all key metrics. Company shows recent insider activity (7 Form 4 filings in 90 days) suggesting active management engagement, but lack of revenue, profitability, and balance sheet transparency prevents any credible assessment of financial health or investment merit.

AKTS Strengths

+ Recent insider activity indicates engaged management team
+ Biopharmaceutical sector allows for potential pipeline value creation
+ Listed on Nasdaq suggests prior compliance with exchange standards

AKTS Risks

! Complete absence of financial reporting data across income statement, balance sheet, and cash flow metrics
! No revenue generation apparent, typical of pre-commercialization biotech
! Inability to assess liquidity, solvency, or operational viability without financial statements

Key Metrics to Watch

* Revenue and gross profit recognition upon any product commercialization
* Cash position and runway given typical biotech cash burn
* Operating cash flow trends and path to profitability or strategic milestone achievement

AKTS Financial Metrics

Revenue

N/A

Net Income

N/A

EPS (Diluted)

$0.00

Free Cash Flow

N/A

Total Assets

N/A

Cash Position

N/A

AKTS Profitability Ratios

Gross Margin N/A

Operating Margin N/A

Net Margin N/A

ROE N/A

ROA N/A

FCF Margin N/A

AKTS Balance Sheet & Liquidity

Current Ratio

N/A

Quick Ratio

N/A

Debt/Equity

N/A

Debt/Assets

0.0%

Interest Coverage

N/A

Long-term Debt

N/A

AKTS Growth Metrics (YoY)

Revenue Growth

N/A

Year-over-year

Net Income Growth

N/A

Year-over-year

EPS Growth

N/A

Earnings per share

FCF Margin

N/A

Free cash flow / Revenue

AKTS SEC Filings

Access official SEC EDGAR filings for Aktis Oncology, Inc. (CIK: 0002035832)

📄 10-K Annual Reports 📋 10-Q Quarterly Reports 📰 8-K Current Reports 📊 Proxy Statements 🔍 All Filings

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.

Data Source: SEC EDGAR | Analysis Date: Mar 19, 2026 | Data as of: 2026-03-19 | Powered by Claude AI